AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Clementia, Multi-Color, and GTx on Behalf of Stockholders and Encourages Investors to Contact the Firm

March 21, 2019

NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Clementia Pharmaceuticals Inc., Multi-Color Corporation, and GTx, Inc. Additional information about each potential action can be found at the link provided.

Clementia Pharmaceuticals Inc. (NASDAQ: CMTA)

Buyer: Ipsen S.A.

Pursuant to the proposed transaction, announced on February 25, 2019 and valued at $1.31 billion, Clementia stockholders will receive $6.00 in cash for each share of Clementia common stock owned. The investigation focuses on whether Clementia and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.

To learn more about the Clementia investigation go to: https://bespc.com/cmta/.

Multi-Color Corporation (NASDAQ: LABL)

Buyer: Platinum Equity LLC

Pursuant to the proposed transaction, announced on February 25, 2019 and valued at $2.5 billion, Multi-Color stockholders will receive $50.00 in cash for each share of Multi-Color common stock owned. The investigation focuses on whether Multi-Color and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.

To learn more about the Multi-Color investigation go to: https://bespc.com/labl/.

GTx, Inc. (NASDAQ: GTXI)

Buyer: Oncternal Therapeutics, Inc.

Pursuant to the proposed transaction, announced on March 7, 2019, current GTx stockholders will own approximately 25% of the combined company. The investigation focuses on whether GTx and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.

To learn more about the GTx investigation go to: https://bespc.com/gtxi/.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Melissa Fortunato, Esq.(212) 308-1869 investigations@bespc.comwww.bespc.com